Wednesday - May 7, 2025
Varex Imaging Corporation (Nasdaq: VREX) today announced that it will report unaudited financial results for the first quarter of fiscal year 2023 following the close of regular trading on Tuesday, January 31, 2023. The earnings news release will be followed by a conference call at 3:00 pm Mountain Time that day.
This call will be webcast live and can be accessed at the company's website at www.vareximaging.com/investors. Investors can also access this conference call at 877-524-8416 from anywhere in the U.S. or 412-902-1028 from non-U.S. locations. The webcast of this call will be archived on the company’s website and a replay of the call will be available from January 31st through February 14th at 877-660-6853 from anywhere in the U.S. or 201-612-7415 from non-U.S. locations. The replay conference call access code is 13735486. The listen-only webcast link is: https://event.choruscall.com/mediaframe/webcast.html?webcastid=YcwMaGcv
About Varex
Varex Imaging Corporation is a leading innovator, designer and manufacturer of X-ray imaging components, which include X-ray tubes, digital detectors and other image processing solutions that are key components of X-ray imaging systems. With a 70+ year history of successful innovation, Varex’s products are used in medical imaging as well as in industrial and security imaging applications. Global OEM manufacturers incorporate the company’s X-ray sources, digital detectors, connecting devices and imaging software in their systems to detect, diagnose, protect and inspect. Headquartered in Salt Lake City, Utah, Varex employs approximately 2,300 people located in North America, Europe, and Asia. For more information visit vareximaging.com.
Last Trade: | US$8.34 |
Daily Change: | -0.11 -1.30 |
Daily Volume: | 159,909 |
Market Cap: | US$343.650M |
February 03, 2025 December 23, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load